Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
doxitinib
- Development stage
- Phase 2
- Lead developer
- Henan Meitaibao Biopharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Doxitinib is a novel, orally active, multi-target tyrosine kinase inhibitor (TKI) developed by Henan Genuine Biotech. It is designed to inhibit tumor growth and angiogenesis by targeting several key signaling pathways, specifically the vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptors (PDGFR), and the mast/stem cell growth factor receptor (c-Kit). By blocking these receptors, doxitinib disrupts the signaling cascades necessary for the formation of new blood vessels that supply tumors and inhibits the proliferation of cancer cells. The drug is currently being evaluated in clinical trials for the treatment of advanced solid tumors, with a particular focus on patients with non-small cell lung cancer (NSCLC) who have failed standard therapies.
- Other names
- doxitinib
02
Targets
EGFR (Epidermal growth factor receptor)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on doxitinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on doxitinib.